News und Analysen

On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (NYSE:PFE), adding shares worth an estimated $6.8 million in the third quarter.

QSM Asset Management increased its position in

Investing in pharmaceutical stocks can carry risks. It's not always clear which drugs will be successful and turn into blockbusters for their respective businesses. As a result, it can take years

Over the past decade, pharmaceutical maker Pfizer (NYSE: PFE) has severely lagged the market. Dividends reinvested aside, the stock is in the red over this period, while the S&P 500 is up by almost

Eli Lilly (NYSE: LLY) is the largest pharmaceutical (and healthcare) company in the world by market capitalization. It boasts more than 49,000 employees and currently leads the fast-growing market

The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.

And

Shares of Omeros (NASDAQ: OMER) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.

It was a deal with the Danish

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

An SEC filing dated

CCLA Investment Management disclosed a purchase of 66,275 shares of Abbott Laboratories (NYSE:ABT) , estimated at ~$8.70 million based on the quarterly average price, in its SEC filing for the

There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of

Robotics has spent decades trapped in the pilot-project phase. Companies ran tests, showcased demos, and projected massive returns that rarely materialized at scale. But something fundamental

Graphene Investments SAS fully exited its position in Centene Corporation (NYSE:CNC) during the third quarter, selling approximately 55,600 shares in a transaction estimated at ~$3.02 million as of

On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (NASDAQ:INCY), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this

One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing

Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a

Charlie Munger had a cheat code for finding great investment ideas: "Looking at what other smart people are buying."

Luckily, finding what other smart people are buying has become much easier over

A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more

On October 10, 2025, Sarasin & Partners LLP disclosed a significant reduction in its UnitedHealth Group (NYSE:UNH) stake, selling 465,744 shares in an estimated $140.86 million trade.

Sarasin &amp

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other artificial intelligence stocks. To learn more, check out the short video, consider subscribing,

Viking Therapeutics (NASDAQ: VKTX) soared to the forefront almost two years ago when it announced data on an investigational drug to serve an area of high need: weight loss. The biotech's candidate

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining

The 6.7% dividend yield on offer from Pfizer (NYSE: PFE) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable. But

Nektar Therapeutics (NASDAQ: NKTR) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January. Yet, some analysts